Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077

(2013) Wolfram Pönisch et al.   BRITISH JOURNAL OF HAEMATOLOGY

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

(2013) Maria T. Petrucci et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe

(2013) Mauro Cives et al.   CELLULAR SIGNALLING

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

(2012) S. Lentzsch et al.   BLOOD

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

(2012) James R. Berenson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

(2012) Wolfram Pönisch et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence

(2011) Eugenio Piro et al.   ACTA HAEMATOLOGICA

Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma

(2011) Elisabeth Grey-Davies et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease

(2011) Karthik Ramasamy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Telomere length is associated with disease severity and declines with age in dyskeratosis congenita

(2011) B. P. Alter et al.   HAEMATOLOGICA

Bendamustine

(2009) Matt Kalaycio   CANCER

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

(2008) Wolfram Pönisch et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

(2008) G. Roue et al.   CLINICAL CANCER RESEARCH

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

(2008) L. M. Leoni et al.   CLINICAL CANCER RESEARCH